Gilead Sciences Inc. has failed in its initial attempts to invalidate two U.S. patents on HIV prevention.
The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) on Wednesday declined to institute administrative review of two patents the government holds on methods for using Gilead’s Truvada medication for HIV prevention.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
